Brindle & Bay Financial Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Brindle & Bay Financial Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$214K	Buy	+1,271	New	+$189K	0.11%	80

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Brindle & Bay Financial Advisors's NBIX Position: Q2 2026 in Review

Brindle & Bay Financial Advisors opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,271 shares worth $214K. The stake represents 0.11% of the portfolio and ranks #80 among its holdings.

770 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Brindle & Bay Financial Advisors held 1,271 shares of Neurocrine Biosciences worth $214K as of Q2 2026.
Neurocrine Biosciences was a new Brindle & Bay Financial Advisors position in Q2 2026.
Neurocrine Biosciences made up 0.11% of Brindle & Bay Financial Advisors's portfolio in Q2 2026, its #80 holding.
770 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Brindle & Bay Financial Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.